US 11,970,546 B2
Antibody specific for Mucin-1 and methods of use thereof
David Rabuka, Kensington, CA (US); Penelope M. Drake, Castro Valley, CA (US); Yun Cheol Kim, Walnut Creek, CA (US); Robyn M. Barfield, Emeryville, CA (US); Maxine Bauzon, Hercules, CA (US); and Ayodele Ogunkoya, Emeryville, CA (US)
Assigned to R.P. SCHERER TECHNOLOGIES, LLC, Carson City, NV (US)
Filed by R.P. Scherer Technologies, LLC, Carson City, NV (US)
Filed on Jul. 30, 2021, as Appl. No. 17/389,723.
Claims priority of provisional application 63/059,497, filed on Jul. 31, 2020.
Prior Publication US 2022/0033514 A1, Feb. 3, 2022
Int. Cl. C07K 16/30 (2006.01); A61K 39/00 (2006.01); A61K 47/69 (2017.01); A61P 35/00 (2006.01)
CPC C07K 16/3076 (2013.01) [A61K 47/6911 (2017.08); A61K 2039/505 (2013.01); A61P 35/00 (2018.01)] 23 Claims
 
1. An antibody or fragment thereof that specifically binds to Mucin-1 (MUC-1), wherein the antibody or fragment thereof comprises:
a heavy chain complementarity determining region 1 (HCDR1), a heavy chain complementarity determining region 2 (HCDR2), and a heavy chain complementarity determining region 3 (HCDR3) as set forth in a variable heavy (VH) chain comprising the amino acid sequence of SEQ ID NO: 1; and
a light chain complementarity determining region 1 (LCDR1), a light chain complementarity determining region 2 (LCDR2), and a light chain complementarity determining region 3 (LCDR3) as set forth in a variable light (VL) chain comprising the amino acid sequence of any one of SEQ ID NOs: 2, 3, or 4.